Neuroinflammation and Staging

doi:10.1017/9781139839518.008

Chapter 8 - Neuroinflammation and Staging

from Section 2 - Progress with Clinical Staging

Published online by Cambridge University Press: 08 August 2019

Bernhard T. Baune

Edited by

Patrick D. McGorry and

Ian B. Hickie

Show author details

Patrick D. McGorry: Affiliation:
University of Melbourne
Ian B. Hickie: Affiliation:
University of Sydney

Book contents

Get access

Summary

The staging model of mental illness is developing beyond the clinical level aiming to include biological processes and markers that may reflect the dynamic biological processes of stages of mental illness. The neurobiology of inflammation in mental illness has gained much attention in recent years. Since neuroinflammation has been shown to be an important possible feature of psychosis, schizophrenia and depression, in this chapter it is attempted to map changes and dysregulation of the immune system and inflammation to the different clinical stages of severe mental illness. The literature suggests that an increased inflammatory response may define a subgroup of individuals in ultra-high-risk states, in acute disease episodes and in those with severe mental illness. In addition, the literature clearly points to the dynamic nature of the immune response in mental illness and shows an involvement of both the innate and adaptive immune system in mental illness. A focus on inflammation only might be insufficient and a broader understanding of the interaction between innate and adaptive immune systems and the complex neuroimmune interaction is required.

Keywords

clinical staging mental disorders biological makers neuroinflammation inflammation oxidative stress neuroprotection omega-3 fatty acids diagnosis intervention

Information

Type: Chapter
Information: Clinical Staging in Psychiatry
Making Diagnosis Work for Research and Treatment
, pp. 172 - 190
DOI: https://doi.org/10.1017/9781139839518.008 [Opens in a new window]
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Aguliar-Valles, A., Kim, J., Jung, S., Woodside, B., & Luheshi, G. N. (2014). Role of brain transmigrating neutrophils in depression-like behavior during systemic infection. Molecular Psychiatry, 19(5), 599–606.Google Scholar

Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., … Kamalipour, A. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression and Anxiety, 26(7), 607–611.Google Scholar

Almeida, O. P., Alfonso, H., Jamrozik, K., Hankey, G. J., & Flicker, L. (2010). Aspirin use, depression, and cognitive impairment in later life: the health in men study. Journal of the American Geriatrics Society, 58(5), 990–992.CrossRef Google Scholar PubMed

Almeida, O. P., Flicker, L., Yeap, B. B., Alfonso, H., McCaul, K., & Hankey, G. J. (2012). Aspirin decreases the risk of depression in older men with high plasma homocysteine. Translational Psychiatry, 2, e151.Google Scholar

Amminger, G. P., Schafer, M. R., Klier, C. M., Slavik, J. M., Holzer, I., Holub, M., … Berk, M. (2012). Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Molecular Psychiatry, 17(12), 1150–1152.Google Scholar

Amminger, G. P., Schafer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., … Berger, G. E. (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry, 67(2), 146–154.Google Scholar

Arion, D., Unger, T., Lewis, D. A., Levitt, P., & Mirnics, K. (2007). Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biological Psychiatry, 62(7), 711–721.Google Scholar

Barbaresko, J., Koch, M., Schulze, M. B., & Nothlings, U. (2013). Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature review. Nutrition Reviews, 71(8), 511–527.Google Scholar

Baune, B. (2009). Conceptual challenges of a tentative model of stress-induced depression. PLoS One, 4(1), e4266.Google Scholar

Baune, B. T. (2015). Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention? Current Opinion in Psychiatry, 28(2), 148–154.Google Scholar

Baune, B. T., Wiede, F., Braun, A., Golledge, J., Arolt, V., & Koerner, H. (2008). Cognitive dysfunction in mice deficient for TNF- and its receptors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B(7), 1056–1064.Google Scholar

Berger, G. E., Wood, S., & McGorry, P. (2003). Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacology Bulletin, 37(2), 79–101.Google Scholar

Berger, G. E., Wood, S. J., Wellard, R. M., Proffitt, T. M., McConchie, M., Amminger, G. P., … McGorry, P. D. (2008). Ethyl-eicosapentaenoic acid in first-episode psychosis: a 1H-MRS study. Neuropsychopharmacology, 33(10), 2467–2473.Google Scholar

Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., … Bush, A. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biological Psychiatry, 64, 361–368.Google Scholar

Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., Ohlenschlaeger, J., le Quach, P., … Nordentoft, M. (2008). Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Archives of General Psychiatry, 65(7), 762–771.Google Scholar

Blank, T., & Prinz, M. (2013). Microglia as modulators of cognition and neuropsychiatric disorders. Glia, 61(1), 62–70.Google Scholar

Borovcanin, M., Jovanovic, I., Radosavljevic, G., Djukic Dejanovic, S., Bankovic, D., Arsenijevic, N., & Lukic, M. L. (2012). Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. Journal of Psychiatric Research, 46(11), 1421–1426.Google Scholar

Calviello, G., Su, H. M., Weylandt, K. H., Fasano, E., Serini, S., & Cittadini, A. (2013). Experimental evidence of omega-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. BioMed Research International, 2013, 743171.Google Scholar

Camara, M. L., Corrigan, F., Jaehne, E. J., Jawahar, M. C., Anscomb, H., & Baune, B. T. (2015). Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology, 40(2), 502–512.CrossRef Google Scholar PubMed

Clark, S. R., Schubert, K. O., & Baune, B. T. (2015). Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome. Journal of Neural Transmission, 122(1), 155–169.Google Scholar

Conradi, H. J., Ormel, J., & De Jonge, P. (2011). Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological Medicine, 41(6), 1165–1174.CrossRef Google Scholar PubMed

Couch, Y., Anthony, D. C., Dolgov, O., Revischin, A., Festoff, B., Santos, A. I., … Strekalova, T. (2013). Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain, Behavior, and Immunity, 29, 136–146.Google Scholar

Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56.Google Scholar

Do, K. Q., Trabesinger, A. H., Kirsten-Krüger, M., Lauer, C. J., Dydak, U., Hell, D., … Cuénod, M. (2000). Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience, 12, 3721–3728.Google Scholar

Dunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., & Allen, J. (2006). Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. Journal of Clinical Psychiatry, 67(5), 688–695.Google Scholar

Erickson, K. I., Gildengers, A. G., & Butters, M. A. (2013). Physical activity and brain plasticity in late adulthood. Dialogues in Clinical Neuroscience, 15(1), 99–108.Google Scholar

Eyre, H. A., Air, T., Proctor, S., Rositano, S., & Baune, B. T. (2014). A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 57C, 11–16.Google Scholar

Eyre, H., & Baune, B. T. (2012). Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology, 37(9), 1397–1416.Google Scholar

Eyre, H. A., & Baune, B. T. (2015). Anti-inflammatory intervention in depression. JAMA Psychiatry, 72(5), 511.Google Scholar

Eyre, H., Papps, E., & Baune, B. T. (2013). Treating depression and depression-like behaviour with physical activity: an immune perspective. Frontiers in Psychiatry, 4, 3.Google Scholar

Fava, G. A., Ruini, C., & Belaise, C. (2007). The concept of recovery in major depression. Psychological Medicine, 37(3), 307–317.Google Scholar

Fields, C., Drye, L., Vaidya, V., & Lyketsos, C. (2012). Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. American Journal of Geriatric Psychiatry, 20(6), 505–513.Google Scholar

Flatow, J., Buckley, P., & Miller, B. J. (2013). Meta-analysis of oxidative stress in schizophrenia. Biological Psychiatry, 74, 400–409.Google Scholar

Fond, G., Hamdani, N., Kapczinski, F., Boukouaci, W., Drancourt, N., Dargel, A., … Leboyer, M. (2014). Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica, 129(3), 163–179.Google Scholar

Freund-Levi, Y., Eriksdotter-Jonhagen, M., Cederholm, T., Basun, H., Faxen-Irving, G., Garlind, A., … Palmblad, J. (2006). Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study – a randomized double-blind trial. Archives of Neurology, 63(10), 1402–1408.Google Scholar

Freund-Levi, Y., Hjorth, E., Lindberg, C., Cederholm, T., Faxen-Irving, G., Vedin, I., … Eriksdotter Jonhagen, M. (2009). Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders, 27(5), 481–490.Google Scholar

Gallagher, P. J., Castro, V., Fava, M., Weilburg, J. B., Murphy, S. N., Gainer, V. S., … Perlis, R. H. (2012). Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. American Journal of Psychiatry, 169(10), 1065–1072.Google Scholar

Garcia-Rizo, C., Fernandez-Egea, E., Oliveira, C., Justicia, A., Bernardo, M., & Kirkpatrick, B. (2012). Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Research, 198(2), 212–215.Google Scholar

Gupta, S., Knight, A. G., Keller, J. N., & Bruce-Keller, A. J. (2012). Saturated long-chain fatty acids activate inflammatory signaling in astrocytes. Journal of Neurochemistry, 120(6), 1060–1071.CrossRef Google Scholar PubMed

Hamer, M., Sabia, S., Batty, G. D., Shipley, M. J., Tabak, A. G., Singh-Manoux, A., & Kivimaki, M. (2012). Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation, 126(8), 928–933.Google Scholar

Haroon, E., Raison, C. L., & Miller, A. H. (2012). Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology, 37(1), 137–162.Google Scholar

Hegelstad, W. T., Larsen, T. K., Auestad, B., Evensen, J., Haahr, U., Joa, I., … McGlashan, T. (2012). Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. American Journal of Psychiatry, 169(4), 374–380.Google Scholar

Hjorth, E., Zhu, M., Toro, V. C., Vedin, I., Palmblad, J., Cederholm, T., … Schultzberg, M. (2013). Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. Journal of Alzheimer’s Disease, 35(4), 697–713.Google Scholar

Insel, T. (2007). The arrival of preemptive psychiatry. Early Intervention in Psychiatry, 1, 5–6.Google Scholar

Jaturapatporn, D., Isaac, M. G., McCleery, J., & Tabet, N. (2012). Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database of Systematic Reviews, 2, CD006378.Google Scholar

Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2001). Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. American Journal of Psychiatry, 158(4), 582–586.Google Scholar

Keshavan, M. S., Sanders, R. D., Pettegrew, J. W., Dombrowsky, S. M., & Panchalingam, K. (1993). Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies. Schizophrenia Research, 10, 241–246.Google Scholar

Kiecolt-Glaser, J. K., Epel, E. S., Belury, M. A., Andridge, R., Lin, J., Glaser, R., … Blackburn, E. (2013). Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. Brain, Behavior, and Immunity, 28, 16–24.Google Scholar

Krstic, D., & Knuesel, I. (2013). Deciphering the mechanism underlying late-onset Alzheimer disease. Nature Reviews: Neurology, 9(1), 25–34.Google Scholar

Labrousse, V. F., Nadjar, A., Joffre, C., Costes, L., Aubert, A., Gregoire, S., … Laye, S. (2012). Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One, 7(5), e36861.Google Scholar

Larsen, T. K., Melle, I., Auestad, B., Haahr, U., Joa, I., Johannessen, J. O., … McGlashan, T. (2011). Early detection of psychosis: positive effects on 5-year outcome. Psychological Medicine, 41(7), 1461–1469.Google Scholar

Latour, A., Grintal, B., Champeil-Potokar, G., Hennebelle, M., Lavialle, M., Dutar, P., … Denis, I. (2013). Omega-3 fatty acids deficiency aggravates glutamatergic synapse and astroglial aging in the rat hippocampal CA1. Aging Cell, 12(1), 76–84.Google Scholar

Lavoie, S., Berger, M., Schlögelhofer, M., Schäfer, M. R., Rice, S., Kim, S. W., … Amminger, G. P. (2017). Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Translational Psychiatry, 7(3), e1064.CrossRef Google Scholar PubMed

Leonard, B., & Maes, M. (2012). Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neuroscience and Biobehavioral Reviews, 36(2), 764–785.Google Scholar

Lewinsohn, P. M., Rohde, P., Seeley, J. R., Klein, D. N., & Gotlib, I. H. (2000). Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. American Journal of Psychiatry, 157(10), 1584–1591.Google Scholar

Libov, I., Miodownik, C., Bersudsky, Y., Dwolatzky, T., Lerner, V. (2007). Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. Journal of Clinical Psychiatry, 68, 1031–1037.Google Scholar

Liu, Y. H., Zeng, F., Wang, Y. R., Zhou, H. D., Giunta, B., Tan, J., & Wang, Y. J. (2013). Immunity and Alzheimer’s disease: immunological perspectives on the development of novel therapies. Drug Discovery Today, 18(23–24), 1212–1220.Google Scholar

Loef, M., & Walach, H. (2013). The omega-6/omega-3 ratio and dementia or cognitive decline: a systematic review on human studies and biological evidence. Journal of Nutrition in Gerontology and Geriatrics, 32(1), 1–23.Google Scholar

Lourida, I., Soni, M., Thompson-Coon, J., Purandare, N., Lang, I. A., Ukoumunne, O. C., & Llewellyn, D. J. (2013). Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology, 24(4), 479–489.Google Scholar

Maes, M., Mihaylova, I., Kubera, M., & Ringel, K. (2012). Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 36(1), 169–175.Google Scholar

Mahar, I., Bambico, F. R., Mechawar, N., & Nobrega, J. N. (2014). Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neuroscience and Biobehavioral Reviews, 38, 173–192.Google Scholar

March, J., Silva, S., Petrycki, S., Curry, J., Wells, K., Fairbank, J., … Treatment for Adolescents with Depression Study Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA, 292(7), 807–820.Google Scholar PubMed

McAfoose, J., & Baune, B. T. (2009). Evidence for a cytokine model of cognitive function. Neuroscience and Biobehavioral Reviews, 33(3), 355–366.Google Scholar

McGorry, P. D. (2007). Issues for DSM-V: clinical staging – a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. American Journal of Psychiatry, 164(6), 859–860.Google Scholar

McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C., & Jackson, H. J. (2006). Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry, 40(8), 616–622.Google Scholar

McGorry, P., Keshavan, M., Goldstone, S., Amminger, P., Allott, K., Berk, M., … Hickie, I. (2014). Biomarkers and clinical staging in psychiatry. World Psychiatry, 13(3), 211–223.Google Scholar

McGorry, P. D., Nelson, B., Goldstone, S., & Yung, A. R. (2010). Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Canadian Journal of Psychiatry, 55(8), 486–497.Google Scholar

Miller, A. H., Maletic, V., & Raison, C. L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65(9), 732–741.Google Scholar

Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry, 70(7), 663–671.Google Scholar

Miller, B. J., Culpepper, N., & Rapaport, M. H. (2014). C-reactive protein levels in schizophrenia. Clinical Schizophrenia & Related Psychoses, 7, 223–230.Google Scholar

Miller, G. E., & Cole, S. W. (2012). Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biological Psychiatry, 72(1), 34–40.CrossRef Google Scholar PubMed

Mizwicki, M. T., Liu, G., Fiala, M., Magpantay, L., Sayre, J., Siani, A., … Teplow, D. B. (2013). 1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer’s disease patients. Journal of Alzheimer’s Disease, 34(1), 155–170.Google Scholar

Monji, A., Kato, T., & Kanba, S. (2009). Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences, 63(3), 257–265.Google Scholar

Monsonego, A., Nemirovsky, A., & Harpaz, I. (2013). CD4 T cells in immunity and immunotherapy of Alzheimer’s disease. Immunology, 139(4), 438–446.Google Scholar

Moylan, S., Berk, M., Dean, O. M., Samuni, Y., Williams, L. J., O’Neil, A., … Maes, M. (2014). Oxidative & nitrosative stress in depression: why so much stress? Neuroscience and Biobehavioral Reviews, 45C, 46–62.Google Scholar

Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013). The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry, 18(5), 595–606.Google Scholar

Muller, N. (2013). The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina, 25(3), 292–298.Google Scholar

Muller, N., Myint, A. M., & Schwarz, M. J. (2011). Inflammatory biomarkers and depression. Neurotoxicity Research, 19(2), 308–318.Google Scholar

Muller, N., Myint, A. M., & Schwarz, M. J. (2012). Inflammation in schizophrenia. Advances in Protein Chemistry and Structural Biology, 88, 49–68.Google Scholar

Muller, N., Riedel, M., Scheppach, C., Brandstatter, B., Sokullu, S., Krampe, K., … Schwarz, M. J. (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry, 159(6), 1029–1034.Google Scholar

Muller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Muller, B., … Riedel, M. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry, 11(7), 680–684.Google Scholar

Musil, R., Schwarz, M. J., Riedel, M., Dehning, S., Cerovecki, A., Spellmann, I., … Muller, N. (2011). Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression: no influence of celecoxib treatment. Journal of Affective Disorders, 134(1–3), 217–225.Google Scholar

Naert, G., & Rivest, S. (2013). A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease. Journal of Molecular Cell Biology, 5(5), 284–293.Google Scholar

Nagelhus, E. A., Amiry-Moghaddam, M., Bergersen, L. H., Bjaalie, J. G., Eriksson, J., Gundersen, V., … Tonjum, T. (2013). The glia doctrine: addressing the role of glial cells in healthy brain ageing. Mechanisms of Ageing and Development, 134(10), 449–459.Google Scholar

Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta-Soares, G. B., Frey, B. N., … Soares, J. C. (2008). Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Human Psychopharmacology, 23(2), 87–94.Google Scholar

Norman, R. M., Manchanda, R., Malla, A. K., Windell, D., Harricharan, R., & Northcott, S. (2011). Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophrenia Research, 129(2–3), 111–115.Google Scholar

Orr, S. K., Trepanier, M. O., & Bazinet, R. P. (2013). n-3 polyunsaturated fatty acids in animal models with neuroinflammation. Prostaglandins, Leukotrienes and Essential Fatty Acids, 88(1), 97–103.Google Scholar

Park, S. E., Dantzer, R., Kelley, K. W., & McCusker, R. H. (2011). Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. Journal of Neuroinflammation, 8, 12.Google Scholar

Pasco, J. A., Jacka, F. N., Williams, L. J., Henry, M. J., Nicholson, G. C., Kotowicz, M. A., & Berk, M. (2010). Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychotherapy and Psychosomatics, 79(5), 323–325.Google Scholar

Ponomarev, E. D., Veremeyko, T., & Weiner, H. L. (2013). MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia, 61(1), 91–103.Google Scholar

Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., … Miller, A. H. (2012). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Archives of General Psychiatry, 70, 31–41.Google Scholar

Ripke, S., Sanders, A. R., Kendler, K. S., Levinson, D. F., Sklar, P., Holmans, P. A., … Cichon, S. (2011). Genome-wide association study identifies five new schizophrenia loci. Nature Genetics, 43(10), 969–976.Google Scholar

Saetre, P., Emilsson, L., Axelsson, E., Kreuger, J., Lindholm, E., & Jazin, E. (2007). Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry, 7, 46.Google Scholar

Schubert, K. O., Clark, S. R., & Baune, B. T. (2015). The use of clinical and biological characteristics to predict outcome following first episode psychosis. Australian and New Zealand Journal of Psychiatry, 49(1), 24–35.Google Scholar

Shamir, E., Barak, Y., Shalman, I., Laudon, M., Zisapel, N., Tarrasch, R., … Weizman, R. (2001). Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Archives of General Psychiatry, 58, 1049–1052.Google Scholar

Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003). Untreated depression and hippocampal volume loss. American Journal of Psychiatry, 160(8), 1516–1518.Google Scholar

Shelton, R. C. (2012). Does concomitant use of NSAIDs reduce the effectiveness of antidepressants? American Journal of Psychiatry, 169(10), 1012–1015.Google Scholar

Shi, J., Levinson, D. F., Duan, J., Sanders, A. R., Zheng, Y., Pe’er, I., … Gejman, P. V. (2009). Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature, 460, 753–757.Google Scholar

Slavich, G. M., & Irwin, M. R. (2014). From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychological Bulletin, 140(3), 774–815.Google Scholar

Stojanovic, A., Martorell, L., Montalvo, I., Ortega, L., Monseny, R., Vilella, E., & Labad, J. (2014). Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology, 41, 23–32.Google Scholar

Terrando, N., Monaco, C., Ma, D., Foxwell, B. M., Feldmann, M., & Maze, M. (2010). Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proceedings of the National Academy of Sciences of the United States of America, 107(47), 20518–20522.Google Scholar

Tobinick, E. L., & Gross, H. (2008). Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Journal of Neuroinflammation, 5, 2.Google Scholar

Torres, K. C., Santos, R. R., de Lima, G. S., Ferreira, R. O., Mapa, F. C., Pereira, P. A., … Romano-Silva, M. A. (2012). Decreased expression of CCL3 in monocytes and CCR5 in lymphocytes from frontotemporal dementia as compared with Alzheimer’s disease patients. Journal of Neuropsychiatry and Clinical Neurosciences, 24(3), E11–E12.Google Scholar

Uher, R., Carver, S., Power, R. A., Mors, O., Maier, W., Rietschel, M., … McGuffin, P. (2012). Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological Medicine, 42(10), 2027–2035.Google Scholar

Videbech, P., & Ravnkilde, B. (2004). Hippocampal volume and depression: a meta-analysis of MRI studies. American Journal of Psychiatry, 161(11), 1957–1966.Google Scholar

Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J., & Greengard, P. (2011). Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 108(22), 9262–9267.Google Scholar

Wyss-Coray, T., & Rogers, J. (2012). Inflammation in Alzheimer disease: a brief review of the basic science and clinical literature. Cold Spring Harbor Perspectives in Medicine, 2(1), a006346.CrossRef Google Scholar PubMed

Xu, M., & He, L. (2010). Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophrenia Research, 120(1–3), 131–142.CrossRef Google Scholar

Yao, J. K., & Keshavan, M. S. (2011). Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxidants & Redox Signaling, 15, 2011–2035.Google Scholar

Zhang, X. Y., Zhou, D. F., Cao, L. Y., Xu, C. Q., Chen, D. C., & Wu, G. Y. (2004). The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology, 24, 83–86.Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the HTML of this chapter is currently unknown and may be updated in the future.